10 Best Genomics Stocks To Buy Right Now

5. CRISPR Therapeutics AG (NASDAQ:CRSP)

Upside potential as of November 14: 48.00%

CRISPR Therapeutics AG (NASDAQ:CRSP) is a gene-editing firm that focuses on the development of CRISPR/Cas9-based therapies. CRISPR/Cas9 is a groundbreaking technology for precisely modifying specific genomic DNA sequences. The company’s primary goal is to treat genetically specified disorders with this technique. This technology precisely breaks DNA to disrupt, delete, correct, and insert genes to treat genetically specified disorders, which is the focus of the company’s unique platform.

CRISPR Therapeutics AG (NASDAQ:CRSP)’s first licensed medication, Casgevy, was created in partnership with Vertex Pharmaceuticals and addresses two conditions with significant unmet medical needs: sickle-cell disease and transfusion-dependent beta-thalassemia. The company is developing several gene editing projects in the fields of cardiovascular disease, immuno-oncology, and a stem cell-derived treatment for Type 1 diabetes.

Through partnerships, some of the expenses associated with clinical development can be covered while CRISPR Therapeutics AG (NASDAQ:CRSP) receives milestones and financial benefits from the advancement of therapeutic proposals.

The company maintains a strong cash position with nearly 1.9 billion in cash and continues to advance its diverse pipeline, including CAR-T and in-vivo therapies.

Analyst Salim Syed of Mizuho Securities has remained enthusiastic about CRISPR Therapeutics AG (NASDAQ:CRSP) stock, with a Buy rating on November 6, 2024. According to the analyst, Casgevy’s price in Saudi Arabia seems to be about $2 million per patient, which is beneficial and more than earlier projections. Strong revenue potential can be seen by this pricing dynamic, which is viewed favorably. Furthermore, Casgevy’s favorable reception in Washington and its strategic alliance with Lonza for global manufacturing, which is expected to satisfy rising demand, support the company’s outlook. Additionally, ARK Invest’s recent acquisitions of CRSP shares show faith in the company’s prospects for the future, which is reinforced by ARK’s recent remarkable performance.